الصفحة الرئيسية>>Signaling Pathways>> Proteases>> Endogenous Metabolite>>Estetrol

Estetrol (Synonyms: E4 15α-Hydroxyestriol)

رقم الكتالوجGC19478

Estetrol هو هرمون الاستروجين الطبيعي الذي يتم تصنيعه حصريًا أثناء الحمل بواسطة كبد الجنين البشري ، وهو مُعدِّل انتقائي لمستقبلات هرمون الاستروجين النووي

Products are for research use only. Not for human use. We do not sell to patients.

Estetrol التركيب الكيميائي

Cas No.: 15183-37-6

الحجم السعر المخزون الكميّة
500µg
63٫00
متوفر
1mg
110٫00
متوفر
5mg
271٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Estetrol is an estrogen steroid hormone exclusively produced by fetal liver from estradiol and estriol during pregnancy. It binds to estrogen receptors (ERs) with 4-fold higher affinity for ERα over ERβ and exhibits estrogenic effects in most tissues expressing ERs (bone, brain, vagina, and endometrium).1,2 In breast tumors, however, estetrol acts as an estrogen antagonist in the presence of estradiol, preventing tumor growth.1,2

Reference:

[1]. Coelingh Bennink, H.J.T., Holinka, C.F., and Diczfalusy, E. Estetrol review: Profile and potential clinical applications Climacteric. 11(Suppl 1), 47-58 (2008).
[2]. Giretti, M.S., Guevara, M.M.M., Cecchi, E., et al. Effects of Estetrol on Migration and Invasion in T47-D Breast Cancer Cells through the Actin Cytoskeleton Front.Endocrinol.(Lausanne) 5(80), 1-8 (2014).

مراجعات

Review for Estetrol

Average Rating: 5 ★★★★★ (Based on Reviews and 13 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Estetrol

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.